UBS analyst Ashwani Verma upgraded Alkermes (ALKS) to Neutral from Sell with a price target of $38, up from $21. UBS has more confidence in Alkermes’ key pipeline drug ALKS-2680, but sees a balanced risk reward on the read-out in the second half of 2025, the analyst tells investors in a research note. The firm believes the upcoming Phase 2 data for ALKS-2680 in narcolepsy type 1 and type 2 studies could generate positive results with strong efficacy, but is cautious on the safety outcome, as while the orexin agonist class has so far generated robust efficacy in narcolepsy, “the jury is still out” on tolerability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes: Hold Rating Amid Declining Base Business Value and Optimistic Orexin Outlook
- Regulatory Challenges Pose Significant Risks to Alkermes’ Financial Stability
- Alkermes plc Reports Record Revenues in 2024 Earnings Call
- Alkermes price target raised to $32 from $30 at Goldman Sachs
- Alkermes outlook reflects underlying strength, says H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com